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A B S T R A C T
Actinomycin D plays a key role in the successful treatment of Wilms tumour. However, associated liver
toxicities remain a drawback to potentially curative treatment. We have used MDCKII cells over-
expressing ABCB1, ABCC1, ABCC2 and ABCG2, alongside knockout mouse models to characterise
actinomycin D transport and its impact on pharmacokinetics. Growth inhibition, intracellular
accumulation and cellular efﬂux assays were utilised. A 59-fold difference in GI50 was observed
between MDCKII-WT and MDCKII-ABCB1 cells (12.7 nM vs. 745 nM, p < 0.0001). Reduced sensitivity
was also seen in MDCKII-ABCC1 and ABCC2 cells (GI50 25.7 and 40.4 nM respectively, p < 0.0001). Lower
intracellular accumulation of actinomycin D was observed in MDCKII-ABCB1 cells as compared to
MDCKII-WT (0.98 nM vs. 0.1 nM, p < 0.0001), which was reversed upon ABCB1 inhibition. Lower
accumulation was also seen in MDCKII-ABCC1 and ABCC2 cells. Actinomycin D efﬂux over 2 h was most
pronounced in MDCKII-ABCB1 cells, with 5.5-fold lower intracellular levels compared to WT. In vivo
studies showed that actinomycin D plasma concentrations were signiﬁcantly higher in Abcb1a/1b/ as
compared to WT mice following administration of 0.5 mg/kg actinomycin D (AUC0–6 h 242 vs. 152 mg/L h
respectively). While comparable actinomycin D concentrations were observed in the kidneys and livers
of Abcb1a/1b/ and Abcc2/ mice, concentrations in the brain were signiﬁcantly higher at 6 h
following drug administration in Abcb1a/1b/mice compared to WT. Results conﬁrm actinomycin D as
a substrate for ABCB1, ABCC1 and ABCC2, and indicate that Abcb1a/1b and Abcc2 can inﬂuence the in
vivo disposition of actinomycin D. These data have implications for ongoing clinical pharmacology trials
involving children treated with actinomycin D.
 2012 Elsevier Inc. 
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First discovered in the 1940s [1], actinomycin D (Act D) now
plays a pivotal role as an anti-tumour antibiotic in the treatment of
several paediatric cancers. As part of a successful multidisciplinary
approach, Act D is a key component in the treatment of Wilms
tumour, resulting in cure rates between 80% and 90% [2,3]. Act D
binds to DNA in a guanine-dependent manner, preventing theAbbreviations: ABC transporter, ATP-binding cassette transporter; Act D, actino-
mycin D; ANOVA, analysis of variance; GI50, concentration at 50% growth
inhibition; LC/MS, liquid chromatography/mass spectrometry; SEM, standard error
of the mean; SNPs, single nucleotide polymorphisms.
* Corresponding author at: Northern Institute for Cancer Research, Paul
O’Gorman Building, Medical School, Framlington Place, Newcastle University,
Newcastle upon Tyne, NE2 4HH, UK. Tel.: +44 0191 246 4332;
fax: +44 0191 222 3452.
E-mail address: G.J.Veal@ncl.ac.uk (G.J. Veal).
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Open access under CC BY-NC-ND license.synthesis of RNA [4] and it has also been shown to inhibit the
incorporation of nucleotide triphosphates into DNA [5].
Act D is a relatively well-tolerated drug with minimal side
effects in the majority of patients in a paediatric setting. However,
a major drawback to Act D treatment is the incidence of liver
toxicities, previously reported in 1.7–13.5% of cases [6–9]. Risk
factors include Wilms tumour, younger age at treatment and dose-
intensity [8]. A pharmacokinetic study published in 2005,
involving 31 patients receiving Act D, indicated a high level of
inter-patient variability in Act D exposure among patients on
similar dosage regimens. Despite the relatively small number of
patients studied, these data suggested that higher concentrations
may correlate with an increased risk of toxicity [10].
ATP-binding cassette (ABC) transporters are present through-
out the body, facilitating the removal of a wide range of substrates
from cells. In the liver, kidney and intestine, p-glycoprotein
(ABCB1/MDR1), multidrug resistance protein 2 (ABCC2/MRP2) and
breast cancer resistance protein (ABCG2/BCRP) are present at the
apical cell membrane, facilitating the elimination of substrates via
.
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membrane at the blood–brain barrier and blood–testis barrier,
protecting vital organs from harmful toxins [12,13]. In contrast,
multidrug resistance protein 1 (ABCC1/MRP1) is present at the
basolateral membrane, facilitating transport of substrates into
blood [14].
Many anti-cancer agents are substrates for ABC transporters,
and as such drug disposition and efﬁcacy can be affected by genetic
variation in expression and function. For example, Abcb1a/1b
knockout mice have been reported to exhibit 1.4-fold higher
plasma concentrations of etoposide compared to wild type (WT)
mice, indicating reduced transporter-mediated drug elimination
[15]. In clinical studies transporter genotype has been shown to
inﬂuence drug exposure for known substrates. Lal et al. reported
that in an Asian breast cancer patient population, individuals who
were homozygous mutant for all three common single nucleotide
polymorphisms (SNPs) of ABCB1 (C1236T, G2677T/A and C3435T)
had signiﬁcantly higher exposure to the anticancer agent
doxorubicin [16].
Although it has long been postulated that Act D is a substrate for
ABCB1 [17–19], with additional studies indicating that ABCC2
plays a role in Act D transport [20], the majority of studies
published in this area involve screening of large numbers of
candidate drugs, as opposed to detailed in vitro and in vivo studies
designed to characterise Act D as a substrate for the major ABC
transport proteins.
Transport of Act D by ABC transporters could be clinically
relevant, with the potential to alter drug exposure and inﬂuence
associated toxicities. As an initial step to investigate the factors
which may impact on the observed inter-patient variation in Act D
exposure [10], the transport of Act D was investigated in vitro using
the Madin–Darby canine kidney-II (MDCKII) cell lines stably over-
expressing human ABCB1, ABCC1, ABCC2 and ABCG2. Experimen-
tal approaches including Act D growth inhibition (GI) studies,
intracellular accumulation assays and a ﬂuorescent competition
assay were utilised. Based on the in vitro data, in vivo studies were
carried out with Abcb1a/1b/ and Abcc2/ mice to investigate
actinomycin D pharmacokinetics and tissue accumulation as
compared to WT. Information from these studies will be relevant
to the analysis of pharmacogenetic data currently being generated
from national clinical pharmacology studies involving the treat-
ment of childhood cancer patients with actinomycin D in both the
US and the UK.
2. Materials and methods
2.1. Chemicals
HPLC-grade solvents (methanol, acetonitrile and acetic acid)
were supplied by Fisher Scientiﬁc (Loughborough, UK), concen-
trated ammonia was supplied by BDH (Dorset, UK). KO143 and
MK571 were from Tocris Bioscience (Bristol, UK), CellTiter 961
AQueous One Solution Cell Proliferation Assay (MTS) substrate was
from Promega Corporation (Southampton, UK) and Pierce protein
assay kits were supplied by Thermo-Scientiﬁc. All other chemicals
were from Sigma–Aldrich (UK).
2.2. Cell lines
Wild-type polarised canine kidney MDCKII cell lines and those
transfected with human ABCB1 (MDR1), ABCC1 (MRP1), ABCC2
(MRP2) and ABCG2 (BCRP), kindly provided by Dr A.H. Schinkel
(Amsterdam, the Netherlands), were used for growth inhibition,
intracellular accumulation assays and the ﬂuorescent competition
assay. Cells were cultured as a monolayer in DMEM with 10% FBS,
2 mM L-glutamate, 2 mM penicillin, and 2 mM of streptomycin, at37 8C, 5% CO2, in a humidiﬁed incubator, and were routinely
screened for mycoplasma.
2.3. Growth inhibition
Growth inhibition (GI) assays were carried out in 96-well plates
(Corning Costar, Amsterdam, the Netherlands). All cells were
seeded at a density of 4000 cells/well on day 0, and allowed to
establish growth over 24 h. Cells were treated with varying
concentrations of Act D on day 1 in the presence or absence of the
appropriate transport inhibitor; verapamil (1 mM) for ABCB1,
MK571 (25 mM) for ABCC1/2 and KO143 (0.2 mM) for ABCG2. Act D
concentrations (0–10 mM) chosen after initial GI experiments
were carried out to determine half-maximal inhibitory concentra-
tion (IC50) values of Act D in these cell lines. Following a 72 h drug
incubation, Promega MTS substrate (12 ml) was added and plates
were returned to the incubator for 2–4 h. The plates were read on a
Spectramax 250 (Molecular Devices, USA) at 490 nm. Results were
reported as a percentage of growth inhibition compared to cells
incubated with medium alone.
2.4. Intracellular accumulation and efﬂux
All cell lines were seeded at 25,000 cells per well in 6-well
plates on day 0 and left to establish growth over 4 days. On day 4
individual plates of cells were incubated with 0.01–2 mM Act D
alone for up to 12 h to determine doses which did not cause cellular
toxicity over deﬁned time periods. Experiments were then carried
out over 12 h with 0.01 mM Act D, or over 4 h with 0.1 mM Act D (to
ensure detectability on the LC/MS), and increasing concentrations
(0–25 mM) of the appropriate inhibitor. For efﬂux experiments, cell
growth was established and cells were incubated with 0.1 mM Act
D for 4 h at 37 8C, 5% CO2 in a humidiﬁed incubator. The medium
was then replaced with medium containing no drug and
intracellular levels were determined at 0, 1 and 2 h to determine
the rate of drug efﬂux. After the deﬁned time course, medium was
removed and the cells were washed twice with 1 ml ice-cold PBS to
remove excess Act D and to prevent any further ABC-mediated
drug transport. Methanol (200 ml) was added to each well and cell
scrapers were used to collect cells. Intracellular Act D concentra-
tions in cell lysates were then determined by LC/MS analysis.
2.5. Fluorescence competition assay
Fluorescence competition assays were carried out in black, clear
bottom 96-well plates (Greiner Bio-One, Stonehouse, UK). MDCKII-
WT and MDCKII-ABCB1 cells were seeded at 1000 cells per well,
and allowed to establish growth over 4 days. Cells were then pre-
incubated with varying levels of Act D (0–100 mM) for 1 h. The
ﬂuorescent ABCB1 substrate doxorubicin (10 mM) was added for a
further 1 h, to assess doxorubicin efﬂux in the presence of Act D.
Hoechst 33342 was used as a nuclear stain once cells had been
formalin ﬁxed and permeabilised with 0.1% Triton-X. Cells were
then imaged for doxorubicin ﬂuorescence on a BD HT Pathway (BD
Biosciences, Oxford, UK). Doxorubicin was excited at 488 nm and a
515 nm long-pass ﬁlter was used to collect emitted ﬂuorescence.
2.6. Animals
All in vivo experiments were reviewed and approved by the
institutional animal welfare committee, and performed according
to National Cancer Research Institute Guidelines [21] and National
Law. Abcb1a/1b/ [22,23], Abcc2/ [24] constitutive knockout
mice, along with the parental FVB strain, were supplied by Taconic
(Hudson, USA) with 12 mice used per strain, 3 mice per time point.
Mice were treated with Act D (Merck Sharp & Dohme, UK) supplied
Fig. 1. Growth inhibitory effects of Act D (0–10 mM) in MDCKII-WT and MDCKII-
ABCB1 cells either alone or in the presence of verapamil (1 mM). Each point
represents mean  SEM from 3 experiments.
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Act D was reconstituted in saline and administered intravenously
at a dose of 0.5 mg/kg via the tail vein.
2.7. Plasma pharmacokinetics of Act D in WT, Abcb1a/1b/ and
Abcc2/ mice
At the appropriate sampling times (15 min, 30 min, 2 h and 6 h),
3 mice were anesthetised with 10 ml/kg of an anaesthetic cocktail
0.75 mg/kg fentanyl citrate, and 25 mg/kg ﬂuanisone (Janssen,
High Wycombe, UK) with 12.5 mg/kg midazolam (Roche, Welwyn
Garden City, UK) and euthanized by cervical dislocation. Blood was
taken via cardiac puncture using a heparin-coated needle (Terumo,
Inchinnan, UK) and syringe (BD Biosciences, Oxford, UK), and
placed in 1.5 ml capped vials. Plasma was separated by centrifu-
gation (1000  g for 5 min) and stored at 20 8C until needed.
From each mouse, liver, kidney and brain samples were also taken
for analysis immediately after blood sampling and stored at 80 8C
until analysis.
2.8. Tissue distribution of Act D in WT, Abcb1a/1b/ and Abcc2/
mice
Tissue samples were washed in PBS, weighed and homogenised
in 3 PBS (1 g tissue: 3 ml PBS). Act D was extracted from all
tissues using acetonitrile and Act D concentrations were deter-
mined in liver and kidneys via the method of addition using
standards in acetonitrile. The method of addition was not used for
brain samples due to volume constraints, with Act D concentra-
tions in the brain reported as peak area. Extracted samples in
acetonitrile were dried down under nitrogen and reconstituted in
50:50 1% acetic acid (pH 4.0) and methanol for LC/MS analysis. All
results were expressed per gram of tissue.
2.9. LC/MS analysis
An API4000 mass spectrometer (Applied Biosystems, CA, USA)
was used for analysis, attached to a Series 200 micropump,
autosampler and peltier column oven (Perkin Elmer Ltd., Beckons-
ﬁeld, UK). A Luna 3m C8 (2) mercury column (20 mm  4 mm)
ﬁtted with a security guard cartridge C8 (4 mm  2 mm) was used
(Phenomenex, Cheshire, UK). A validated LC/MS was used for
analysis; using 1% acetic acid pH 4 and 100% methanol as mobile
phases [25]. Samples in methanol were diluted appropriately,
combined with 1% acetic acid (pH 4.0) and a 50:50 solution
injected onto the LC/MS.
2.10. Statistical analysis
For growth inhibition assays, non-linear regression was
performed, with upper limit set to 100% and lower limit set to
0%. An F-test was then used to compare GI50 values. For
intracellular accumulation and cellular efﬂux assays, two-way
analysis of variance (ANOVA) was used to assess both cell line andTable 1
Growth inhibitory effects of Act D in MDCKII cell lines over-expressing speciﬁc drug tr
MDCKII-WT MDCKII-ABCB1 MD
GI50 (nM) 95% CI GI50 (nM) 95% CI GI5
Act D 12.7 – 745 (680.8, 905.3) 25.
Act D + verapamil 4.4 (3.31, 5.85) 129 (109.8, 150.5) – 
Act D + MK571 4.1 (3.02, 5.55) – – 5.
Act D + KO143 13.1 (10.2, 16.9) – – – 
–, not applicable.
GI50 assessed by MTS assay after 72 h of drug exposure. Values are the mean of 3 exinhibitor effect. GraphPad Prism 5.04 was used for all statistical
analysis. WinNonlin Professional Version 5.3 software (Pharsight
Corp., Mountain View, CA) was used to calculate the area under
the plasma concentration–time curve to 6 h (AUC0–6 h) and to
estimate area under the plasma concentration–time curve to
inﬁnity (AUC0–1) and t1/2.
3. Results
3.1. Impact of ABC transporter expression on growth inhibition
To determine the inﬂuence of ABC transporters on growth
inhibition, MDCKII-WT, MDCKII-ABCB1, MDCKII-ABCC1, MDCKII-
ABCC2 and MDCKII-ABCG2 cell lines were incubated with Act D.
ABCB1 over-expressing cell lines were 59-fold less sensitive than
the parental cell lines (GI50 values 745 nM vs. 12.7 nM, p < 0.0001),
indicating that Act D undergoes ABCB1-mediated efﬂux (Fig. 1 and
Table 1). Inhibition of ABCB1 with verapamil (1 mM) over a 72 h
period resulted in a partial reversal of resistance in the MDCKII-
ABCB1 cell line, with a 6-fold decrease in GI50 (745 nM vs. 129 nM,
p < 0.0001, Fig. 1 and Table 1). Inhibition with verapamil also
caused a 3-fold reduction (12.7 nM vs. 4.4 nM, p < 0.0001) in GI50
in the parental cell line, due to inhibition of endogenous canine
ABCB1.
Both ABCC1 (Fig. 2A) and ABCC2 (Fig. 2B) over-expressing cell
lines showed reduced sensitivity to Act D compared to the parental
cell line. GI50 values were 25.7 nM for ABCC1 and 40.4 nM for
ABCC2, compared to the parental GI50 of 12.7 nM (p < 0.0001,
Table 1), indicating that Act D may be a substrate for ABCC1 and
ABCC2. To further investigate this, experiments were carried out
with the pan ABCC family inhibitor MK571. MK571 (25 mM)
increased sensitivity to Act D by 3-fold in the parental cell line
(p < 0.0001), whilst a greater than 4-fold increase was seen in
MDCKII-ABCC1 (p < 0.0001). There was no effect on the sensitivity
of the MDCKII-ABCC2 cell line (p = 0.23) (Fig. 2C–E and Table 1).ansporters.
CKII-ABCC1 MDCKII-ABCC2 MDCKII-ABCG2
0 (nM) 95% CI GI50 (nM) 95% CI GI50 (nM) 95% CI
7 (18.3, 36.1) 40.4 (32.2, 50.7) 14.0 (11.7, 16.8)
– – – – –
90 (3.35, 10.4) 32.3 23.3, 44.7) – –
– – – 13.0 (10.3, 15.4)
periments.
Fig. 2. Growth inhibition of Act D (0–10 mM) in MDCKII-WT and MDCKII-ABCC1 (A), MDCKII-ABCC2 (B) and MDCKII-ABCG2 (F) cells alone or in the presence of a transporter
inhibitor (ABCC1/ABCC2 – MK571 (25 mM), ABCG2 – KO143 (0.2 mM)) (C, D, E and F). Each point represents mean  SEM from 3 experiments.
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cell line and ABCG2 over-expressing cells, when incubated with Act
D alone or in combination with the speciﬁc ABCG2 inhibitor KO143
(p = 0.74; Fig. 2F and Table 1).
3.2. Intracellular accumulation of Act D in MDCKII cell lines
To conﬁrm the results obtained from growth inhibition
experiments, intracellular accumulation of Act D was investigated
in all cell lines. When incubated for between 2 and 12 h with Act D
alone, a time-dependent accumulation of Act D was observed in all
cell lines (Fig. 3A). Accumulation of Act D was 9.8-fold lower in
MDCKII-ABCB1, compared to the parental cell line (0.1 nM vs.
0.98 nM, p < 0.0001, Fig. 3A and Table 2). Intracellular Act D
concentrations in MDCKII-ABCB1 cells were signiﬁcantly lowerthan WT at 4 h (p < 0.05), 6 h (p < 0.0001) and 12 h (p < 0.0001).
When co-incubated with verapamil, intracellular levels of Act D
increased in a concentration-dependent manner, indicating that
Act D efﬂux is reduced in the presence of ABCB1 inhibition (Fig. 3B).
Treating MDCKII-ABCB1 cells with 10 mM verapamil caused a 7.9-
fold increase in intracellular Act D (p < 0.01). Reversal of resistance
was achieved with verapamil concentrations of 10 mM or greater.
Accumulation studies over 12 h indicated that Act D is also
transported by ABCC1 and ABCC2, with 2.5-fold and 3.5-fold lower
accumulation respectively, compared to the parental cell line
(p < 0.0001; Fig. 3A). Intracellular Act D concentrations in MDCKII-
ABCC1 cells were signiﬁcantly lower than WT at 12 h (p < 0.0001).
Intracellular Act D concentrations in MDCKII-ABCC2 cells were
signiﬁcantly lower than WT at 6 h (p < 0.01) and 12 h (p < 0.0001).
A small trend of increased accumulation, compared to the absence
Fig. 3. Intracellular accumulation of Act D following incubation with Act D (0.01 mM) over 12 h in MDCKII-WT, MDCKII-ABCB1, MDCKII-ABCC1, MDCKII-ABCC2 and MDCKII-
ABCG2 cell lines (A). Intracellular accumulation with Act D (0.1 mM) over 4 h in the presence of a speciﬁc inhibitor (ABCB1 – verapamil, ABCC1/ABCC2 – MK571, ABCG2 –
KO143), with MDCKII-WT and MDCKII-ABCB1 (B) and MDCKII-WT, MDCKII-ABCC1 and MDCKII-ABCC2 (C). Cellular efﬂux after a 4 h incubation with 0.1 mM Act D in all
MDCKII cell lines (D). Each point represents mean  SEM from 3 experiments. **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with MDCKII-WT at the same time point.
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ABCC2) was seen when co-incubating Act D with MK571, but was
not statistically signiﬁcant (Fig. 3C).
Act D accumulation in MDCKII-ABCG2 cell lines was not
different to WT cells (Fig. 3A) and no effect was seen with co-
incubation of Act D and KO143 (data not shown).Table 2
Act D plasma concentrations and pharmacokinetic parameters in WT, Abcb1a/1b/
and Abcc2/ mice following intravenous administration of 0.5 mg/kg Act D.
Act D concentration (mg/L)
WT Abcb1a/1b/ Abcc2/
0.25 h 68.6  15.6 96.7  12.0* 48.0  11.1
0.5 h 43.3  7.68 71.6  12.3* 37.7  6.07
2 h 25.8  4.78 35.8  2.01 16.3  3.73
6 h 6.0  0.65 20.1  0.78 8.6  0.96
AUC0–6 h (mg/L h) 151.5 242.0 114.8
AUC0–1 (mg/L h) 168.1 322.6 145.2
Cmax (mg/L) 68.6  15.6 96.7  12.0 48.0  11.1
Tmax (h) 0.25 0.25 0.25
t1/2 (h) 1.92 2.78 2.46
Individual plasma concentration time points are mean  SD from 3 mice.
* p < 0.05 compared to the WT.3.3. Cellular efﬂux of Act D in MDCKII cell lines
To further conﬁrm results from both the GI and intracellular
accumulation assays, Act D efﬂux from cell lines was assessed
following a 4 h initial uptake period. Over a 2 h period following
drug removal, a time-dependent reduction in intracellular Act D
was seen in all cell lines. MDCKII-ABCB1 cellular efﬂux was again
the most pronounced, with a 5.5-fold reduction over 2 h (Fig. 3D,
p < 0.01). Intracellular Act D concentrations in MDCKII-ABCB1
cells were signiﬁcantly lower than WT at 0 h (p < 0.0001), 1 h
(p < 0.001) and 2 h (p < 0.01). In support of both GI and
intracellular accumulation assay data, efﬂux over 2 h in MDCKII-
ABCC1 and MDCKII-ABCC2 cells was greater than the parental cell
line with a 1.9- and 2.1-fold reduction in intracellular Act D
respectively (Fig. 3D). Although, intracellular Act D was 1.5-fold
higher in MDCKII-ABCG2 cells after 2 h, this difference was not
statistically signiﬁcant.
3.4. Drug transport competition assay using the ﬂuorescent ABCB1
substrate doxorubicin and Act D
Competition for ABCB1-mediated efﬂux was used to conﬁrm
the results obtained from Act D growth inhibition and intracellular
drug accumulation experiments (Fig. 4). Pre-incubation with Act D
Fig. 4. Act D competition assay using the ﬂuorescent ABCB1 substrate doxorubicin. MDCKII-WT and MDCKII-ABCB1 cell lines were pre-incubated with varying levels of Act D
for 1 h and 10 mM of ﬂuorescent ABCB1 substrate doxorubicin was added for a further 1 h, to assess doxorubicin efﬂux in the presence of Act D.
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ﬂuorescent ABCB1 substrate doxorubicin. Intracellular doxorubi-
cin levels in the parental cells plateaued at low Act D concentra-
tions (0.1–1 mM), whereas in the ABCB1 over-expressing cell line
concentrations of 1–25 mM were required to maximally inhibit
doxorubicin efﬂux.
3.5. Impact of Abcb1a and Abcc2 on plasma pharmacokinetics of Act D
To investigate the role of Abcb1a/1b and Abcc2 on the
pharmacokinetics of Act D, Act D was administered at a dose of
0.5 mg/kg to WT, Abcb1a/1b/ and Abcc2/ mice and blood
samples were taken at 15 min, 30 min, 2 h and 6 h. PlasmaFig. 5. Act D (0.5 mg/kg) was administered to wild-type, Abcb1a/1b/ and Abcc2/mice
2 h and 6 h and Act D concentrations were determined by LC/MS analysis. (A) Inset – semconcentrations were consistently higher in Abcb1a/1b/ mice
than WT (Fig. 5A and Table 2) over the 6 h period. The Cmax at
15 min was 1.4-fold higher in Abcb1a/1b/mice compared to WT
(96.7 vs. 68.6 mg/L, p < 0.05) and at 30 min, the difference was 1.7-
fold (71.6 vs. 43.3 mg/L, p < 0.05). Abcb1a/1b/ mice had a 1.6-
fold higher AUC0–6 h (AUC0–6 h; 242 vs. 152 mg/L h). In addition, the
elimination half-life (t1/2) was 1.5-fold longer in Abcb1a/1b
/
mice, resulting in a 1.9-fold greater AUC0–1 (323 vs. 168 mg/L h).
The absence of systemic Abcb1a/1b is associated with a reduced
rate of elimination of Act D and a higher overall drug exposure.
In contrast to Abcb1a/1b/mice, Abcc2/mice generally had
lower plasma concentrations of Act D than WT (Fig. 5A), however
this difference did not reach statistical signiﬁcance. AUC0–6 h and. Blood (A), liver (B), kidney (C) and brain (D) samples were taken at 15 min, 30 min,
i-logarithmic representation of data. Each point represents mean  SEM from 3 mice.
Table 3
Act D tissue disposition concentrations and pharmacokinetic parameters in WT, Abcb1a/1b/ and Abcc2/mice following intravenous administration of 0.5 mg/kg Act D.
Liver concentration (mg/L) Kidney concentration (mg/L) Brain peak area (pa)
WT Abcb1a/1b/ Abcc2/ WT Abcb1a/1b/ Abcc2/ WT Abcb1a/1b/ Abcc2/
0.25 h 1810  155 2323  239 1317  302 13,323  3960 13,207  1025 13,107  2318 1071  217 1134  635 972  455
0.5 h 1593  167 1367  133 1540  356 10,713  2498 13,163  2521 10,593  944 775.3  127 1420  521 1039  181
2 h 747  165 737  172 787  99 4693  415 5327  1257 4987  161 501  28.9 912.7  461 424.3  120
6 h 287  40 407  9 303  128 1970  150 2957  872 3410  527 309  156 1383  439 733  470
AUC0–6 h (mg/L h) 4473 4616 4445 29,552 35,381 33,079 2943 6802 3785
AUC0–1 (mg/L h) 5387 6594 5516 35,754 46,701 48,799 ND ND ND
Cmax (mg/L) 1810  155 2323  239 1540  356 13,323  3960 13,207  1025 13,107  2318 1071  217 1420  521 1039  181
Tmax (h) 0.25 0.25 0.5 0.25 0.25 0.25 0.25 0.5 0.5
t1/2 (h) 2.21 3.37 2.44 2.18 2.65 3.2 ND ND ND
Individual tissue concentration time points are expressed per gram of tissue and are the mean  SD from 3 mice. All brain data is expressed as peak area. ND, no data.
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/mice were lower than in WT mice (115 vs.
152 mg/L h and 48.0 vs. 68.6 mg/L in Abcc2/ and WT mice,
respectively). The t1/2 in Abcc2
/ mice was longer than in the
parental (2.46 vs. 1.92 h), and consequently a similar AUC0–1 for
parental and Abcc2/ was observed (168 vs. 145 mg/L h).
3.6. Effect of Abcb1a and Abcc2 on tissue disposition of Act D
Act D liver concentrations were comparable between knockout
and WT mice over the 6 h period (Fig. 5B and Table 3), with no
signiﬁcant overall effect of ABC transporter knockout on disposi-
tion in the liver. Similarly in the kidneys, comparable AUC0–6 h and
Cmax values were observed in knockout and WT mice (Fig. 5C and
Table 3). Act D brain uptake was comparable between different
groups at 15 min (Fig. 5D and Table 3). This was followed by a time-
dependent decrease in Act D brain concentration in WT mice. In
contrast, Act D concentrations in brain tissue of Abcb1a/1b/ and
Abcc2/mice were maintained over 6 h, resulting in 2.3- and 1.3-
fold higher AUC0–6 h respectively compared to WT, (6802 and 3785
vs. 2943 pa/g h). Act D levels in brain tissue of Abcb1a/1b/mice
were signiﬁcantly higher than those in WT mice at 6 h (p < 0.05).
4. Discussion
Despite Act D being used clinically for over 40 years, little is
known about its clinical pharmacology. To learn more about Act D
disposition, an initial pharmacokinetic study carried out by our
group demonstrated the extent of variation in Act D exposure in a
paediatric patient population [10]. A >4-fold range in area under
plasma concentration–time curve (AUC0–6 h) between patients was
observed and a correlation was seen between higher Act D
exposure and toxicity. Patient age at treatment has been
highlighted as a risk factor for Act D mediated toxicity, with
greater toxicity seen in patients younger than 3 years of age
[10,26], whilst a more recent study has indicated an increased risk
for patients <1 year old [8].
Initial investigations into Act D pharmacokinetics indicate rapid
elimination following intravenous administration and accumula-
tion in nucleated cells, with little of the administered drug excreted
or metabolised [27,28]. Characterisation of the transport of Act D
by ABC transporters may represent an important step in
understanding the inter-patient variability in Act D pharmacoki-
netics and treatment-related toxicities [6–10]. Cellular resistance
to Act D was originally reported by Biedler et al. in a Chinese
hamster ovary model [17], which was later conﬁrmed to be caused
by a cell surface p-glycoprotein [18]. However, transport by ABCB1
or other ABC transporters has not been fully characterised.
In the current study the transport of Act D by a number of ABC
transporters was investigated. Using the well-studied MDCKII cell
line model, we initially conﬁrmed that Act D is a substrate forABCB1 through growth inhibition assays, with a 59-fold difference
in sensitivity between the parental and ABCB1 over-expressing cell
line. This indicates that Act D is efﬂuxed from MDCKII-ABCB1 cells,
therefore decreasing its growth inhibitory effect. Verapamil was
subsequently used to successfully reverse this resistance, con-
ﬁrming the role of ABCB1 in decreasing the growth inhibitory
effect. While a complete reversal of the difference in sensitivity
was not observed in the ABCB1 over-expressing cells, this is likely
to be due to the requirement for a relatively low concentration of
verapamil of 1 mM to be used in these experiments, to avoid any
effects of verapamil itself on cell viability over the 72 h drug
incubation period. With regard to the use of verapamil for these
experiments, it should also be noted that in addition to its activity
as an inhibitor of ABCB1, verapamil has also been shown to exhibit
inhibitory effects against ABCC1 [29].
Transport was further investigated by looking directly at
intracellular concentrations of Act D in MDCKII-WT and
MDCKII-ABCB1 cell lines. A 7.9-fold lower intracellular accumula-
tion was observed in cells over-expressing ABCB1 at a ﬁxed
concentration of Act D (0.01 mM) over a 12 h period, conﬁrming
that Act D was being actively removed from the MDCKII-ABCB1
cells by ABCB1. Again, verapamil was used to inhibit ABCB1-
mediated transport, resulting in a concentration dependent
increase in Act D accumulation in MDCKII-ABCB1 cells, with
complete reversal of the ABCB1-induced efﬂux observed at
verapamil concentrations of 10 mM and above. Cellular efﬂux
experiments following removal of drug conﬁrmed lower Act D
accumulation in ABCB1 expressing cells, followed by a 5.5-fold
time-dependent reduction in intracellular levels that was not seen
in the parental cell line.
Using an uptake competition assay we demonstrated that
doxorubicin ﬂuorescence was reduced in MDCKII-ABCB1 cells, as
compared to MDCKII-WT cells, due to efﬂux of this well established
ABCB1 substrate. Incubating cells with increasing concentrations
of Act D resulted in competition for ABCB1 efﬂux, inhibiting
doxorubicin removal from cells. This caused an increase in
doxorubicin ﬂuorescence in both cell lines, further conﬁrming
Act D as an ABCB1 substrate. Due to the over-expression of ABCB1,
a greater concentration of Act D was required to saturate the
transporter and prevent doxorubicin efﬂux in MDCKII-ABCB1 cells
compared to MDCKII-WT. These four independent assessments
illustrate the importance of ABCB1 expression for the pharmacol-
ogy of Act D.
Growth inhibition assays showed a reduction in sensitivity in
both MDCKII-ABCC1 and MDCKII-ABCC2 cells when treated with
Act D. Over 12 h, accumulation of Act D was signiﬁcantly lower in
both MDCKII-ABCC1 (2.45-fold) and MDCKII-ABCC2 (3.5-fold) cell
lines, compared to MDCKII-WT, indicating active ABCC1- and
ABCC2-mediated efﬂux. Although the pan ABCC family inhibitor
MK571 caused a concentration-dependent increase in Act D
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lines, this was not signiﬁcant. In cellular efﬂux experiments a
signiﬁcant time-dependent reduction in intracellular Act D was
observed over 1 h in ABCC2 over-expressing cells (1.8-fold),
compared to the parental cell line, further supporting the GI and
intracellular accumulation assay data suggesting ABCC2-mediated
transport. No evidence of Act D transport by ABCG2 was found
during growth inhibition, intracellular accumulation or cellular
efﬂux assays.
Transport of anti-cancer agents in animal models is well
characterised and a number of appropriate models are available
[15,30–32]. To assess the potential clinical impact of this work,
pharmacokinetic studies were carried out with Act D (0.5 mg/kg) in
Abcb1a/1b and Abcc2 knockout mice. Act D plasma concentrations
in Abcb1a/1b/ were consistently higher than WT over a 6 h
period following drug administration, resulting in a 1.6-fold higher
AUC0–6 h. Half-life was also longer in Abcb1a/1b
/ mice, and the
AUC0–1 was 1.9-fold higher than that in the WT. Thus, Abcb1a/1b
knockout had a signiﬁcant impact on Act D elimination, resulting in
higher plasma concentrations compared to WT.
Interestingly, higher Act D accumulation was not seen in either
the liver or kidneys of Abcb1a/1b/ mice. Although higher liver
concentrations were initially observed in Abcb1a/1b/ mice at
15 min, Act D liver concentrations decreased over the 6 h in all
mice variants, and consequently no differences in AUC0–6 h were
observed. Contrary to both liver and kidney data, higher
concentrations of Act D were seen in brain tissue from Abcb1a/
1b/ compared to WT. Over the 6 h studied, a time-dependent
reduction in Act D brain concentration was seen in WT mice,
whereas Act D levels in the brain of Abcb1a/1b/ mice were
maintained. Overall exposure to the brain over a 6 h period was
2.3-fold higher in Abcb1a/1b/ mice versus WT.
Mean plasma concentrations in Abcc2/ mice were consis-
tently lower than those in WT, however this difference was not
signiﬁcant. Similarly there were no signiﬁcant differences in tissue
distribution between the knockout animals and WT.
The data presented in the current study conﬁrm that Act D is
transported by ABCB1 and to some extent ABCC1 and ABCC2 in
vitro. Knockout of both Abcb1a and Abcb1b reduces the elimina-
tion of Act D from plasma, resulting in higher plasma concentra-
tions. Interestingly these higher plasma concentrations did not
affect tissue accumulation in the liver or kidneys, but did appear to
alter penetration across the blood–brain barrier brain. Conversely,
there was minimal effect of Abcc2 knockout on Act D plasma
concentrations. The absence of differences in distribution to liver
and kidneys of bcb1a/1b/ mice may be due to the reciprocal
expression of Abcc2. An investigation using a double knockout
mouse model (Abcb1a/1b/, Abcc2/) may therefore be infor-
mative.
Irrespective of transporter knockout genotype, Act D accumu-
lation over 6 h in the kidneys was 6.6- to 7.7-fold higher than the
liver, potentially identifying the kidney as the primary route for Act
D elimination from the body. This would be in agreement with
previous studies which have failed to identify Act D metabolites in
clinical samples.
As Abcb1a/1b has been shown to be involved in the in vivo
disposition of Act D, it would be important to investigate whether
common single nucleotide polymorphisms (SNPs) in ABCB1 could
be responsible for inter-patient variation in Act D exposure.
Correlating clinical parameters to patient genotype could
potentially have great clinical beneﬁt in predicting response
and toxicity, leading to dose individualisation based on pharma-
cogenetic variation. The ﬁndings from the current study will feed
directly into a national clinical trial investigating the pharmaco-
kinetics and pharmacogenetics of Act D in children with cancer in
the UK.Acknowledgment
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